Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5346020 | 0.99 | HRH3 (0.50) | HRH3SIGMAR1HTR1AADRA1DADRA1A | |
| SCHEMBL5343250 | 0.89 | HRH3 (0.47) | HRH3SIGMAR1HTR1AADRA1DADRA1A | |
| SCHEMBL14492171 | 0.87 | ALDH1A1 (0.42) | SIGMAR1HTR1AADRA1DADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL5339941 | 0.86 | ALDH1A1 (0.42) | SIGMAR1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL5347690 | 0.80 | HSD11B1 (0.36) | — | |
| Hydrochloric Acid SCHEMBL5346017 | 0.79 | HSD11B1 (0.36) | — | |
| Hydrochloric Acid SCHEMBL5348090 | 0.79 | ALDH1A1 (0.39) | SIGMAR1 | |
| SCHEMBL14492177 | 0.79 | ALDH1A1 (0.39) | SIGMAR1 | |
| SCHEMBL5344095 | 0.79 | ALDH1A1 (0.40) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL5344733 | 0.78 | ALDH1A1 (0.39) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208495-B2 | Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-24 | — | — | US | claimed |
| US-20070149558-A1 | Benzo-fused 5-membered heterocyclic compounds, their production and use | OHKAWA SHIGENORI | 2007-06-28 | — | — | US | disclosed |
| US-20070149558-A1 | Benzo-fused 5-membered heterocyclic compounds, their production and use | OHKAWA SHIGENORI | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149558-A1 | Benzo-fused 5-membered heterocyclic compounds, their production and use | CBR1, DBH, PARK7 | HRH3 219/4885SIGMAR1 662/4885HTR1A 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.